Rapivab
Marketed by: Biocryst Pharmaceuticals, IncIndication: The FDA has approved Rapivab (peramivir), an influenza virus neuraminidase inhibitor, for the treatment of acute uncomplicated influenza in adults who have been symptomatic for no more than 2 days. The recommended dosage is a single dose of 600 mg administered by intravenous infusion for a minimum of 15 minutes within 2 days of the onset of influenza symptoms. The dosage should be reduced to 200 mg for patients with a baseline creatinine clearance of 30 to 49 mL/min, and reduced to 100 mg for patients with a baseline creatinine clearance of 10 to 29 mL/min.Dosage Form: Injection: 200 mg in 20 mL (10 mg/mL) in a single-use vialFor More Information: www.rapivab.comCosentyx
Marketed by: Novartis PharmaceuticalsIndication: The FDA has approved Cosentyx (secukinumab), a human interleukin-17A antagonist, for the treatment of adults with active ankylosing spondylitis or active psoriatic arthritis. For the recommended dosages, see the full prescribing information.Dosage Form: Injection: 150-mg/mL solution in a single- use pen or prefilled syringe, or 150 mg of lyophilized powder in a single-use vial for reconstitutionFor More Information: cosentyx.comBasaglar
Marketed by: Eli Lilly and CompanyIndication: The FDA has approved Basaglar (insulin glargine injection), a long-acting human insulin analog, for improving glycemic control in adults and pediatric patients with type 1 diabetes mellitus, and in adults with type 2 diabetes mellitus. The dosage should be individualized based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. Basaglar should be administered subcutaneously once daily at any time of day, but at the same time every day.Dosage Form: Injection: 100 units/ mL (U-100) in 3-mL prefilled Basaglar KwikPen delivery deviceFor More Information: basaglar.comQuilliChew ER
Marketed by: PfizerIndication: The FDA has approved QuilliChew ER (methylphenidate hydrochloride), a central nervous system (CNS) stimulant, for the treatment of attention-deficit/ hyperactivity disorder. For patients 6 years and older, the recommended starting dose is 20 mg orally, once daily in the morning. The dosage may be titrated weekly in increments of 10 mg, 15 mg, or 20 mg per day. A daily dosage above 60 mg is not recommended.Dosage Form: Extended-release chewable tablets: 20 mg and 30 mg of methylphenidate hydrochloride (HCl), functionally scored Extended-release chewable tablets: 40 mg of methylphenidate HCl, not scoredFor More Information: pfizer.com/products/product-detail/ quillichew_erOtiprio
Marketed by: Otonomy, IncIndication: The FDA has approved Otiprio (ciprofloxacin otic suspension), a fluoroquinolone antibacterial, for the treatment of pediatric patients with bilateral otitis media with effusion who are undergoing tympanostomy tube placement. Otiprio should be administered as a single intratympanic dose of one 0.1-mL (6 mg) into each affected ear, following suctioning of middle ear effusion.Dosage Form: Otic suspension: Each Otiprio vial contains 1 mL of 6% (60 mg/mL) ciprofloxacin otic suspensionFor More Information: otiprio.com
